Antipsychotic

Antipsychotic
Drug class
Olanzapine, an example of a second-generation (atypical) antipsychotic
Class identifiers
SynonymsNeuroleptics, major tranquilizers[1]
UsePrincipally: Schizophrenia, Schizoaffective disorder, Dementia, Tourette syndrome, Bipolar disorder, irritability in autism spectrum disorder
Clinical data
Drugs.comDrug Classes
External links
MeSHD014150
Legal status
In Wikidata

Antipsychotics, previously known as neuroleptics[1] and major tranquilizers,[2] are a class of psychotropic medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia but also in a range of other psychotic disorders.[3][4] They are also the mainstay, together with mood stabilizers, in the treatment of bipolar disorder.[5] Moreover, they are also used as adjuncts in the treatment of treatment-resistant major depressive disorder.

The use of antipsychotics may result in many unwanted side effects such as involuntary movement disorders, gynecomastia, impotence, weight gain and metabolic syndrome. Long-term use can produce adverse effects such as tardive dyskinesia, tardive dystonia, tardive akathisia, and brain tissue volume reduction.

First-generation antipsychotics (e.g., chlorpromazine, haloperidol, etc.), known as typical antipsychotics, were first introduced in the 1950s, and others were developed until the early 1970s.[6] Second-generation antipsychotics, known as atypical antipsychotics, arrived with the introduction of clozapine in the early 1970s followed by others (e.g., risperidone, olanzapine, etc.).[7] Both generations of medication block receptors in the brain for dopamine, but atypicals block serotonin receptors as well. Third-generation antipsychotics were introduced in the 2000s and offer partial agonism, rather than blockade, of dopamine receptors.[8] Neuroleptic, originating from Ancient Greek: νεῦρον (neuron) and λαμβάνω (take hold of)—thus meaning "which takes the nerve"—refers to both common neurological effects and side effects.[9]

  1. ^ a b Finkel R, Clark MA, Cubeddu LX (2009). Pharmacology. Lippincott Williams & Wilkins. p. 151. ISBN 978-0-7817-7155-9. Archived from the original on 1 April 2017.
  2. ^ Burnett GB (1975). "The assessment of thiothixene in chronic schizophrenia. A double-blind controlled trial". Dis Nerv Syst. 36 (11): 625–9. PMID 1102277.
  3. ^ Bartoli F, Cavaleri D, Callovini T, Riboldi I, Crocamo C, D'Agostino A, Martinotti G, Bertolini F, Ostuzzi G, Barbui C, Carrà G (March 2022). "Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study". Psychiatry Research. 309: 114405. doi:10.1016/j.psychres.2022.114405. PMID 35093701. S2CID 246054926.
  4. ^ Lally J, MacCabe JH (June 2015). "Antipsychotic medication in schizophrenia: a review". British Medical Bulletin. 114 (1): 169–79. doi:10.1093/bmb/ldv017. PMID 25957394. Antipsychotic medications are mainstays in the treatment of schizophrenia and a range of other psychotic disorders.
  5. ^ Grande I, Berk M, Birmaher B, Vieta E (April 2016). "Bipolar disorder". Lancet. 387 (10027): 1561–1572. doi:10.1016/S0140-6736(15)00241-X. PMID 26388529. S2CID 205976059.
  6. ^ Shen WW (December 1999). "A history of antipsychotic drug development". Comprehensive Psychiatry. 40 (6): 407–14. doi:10.1016/s0010-440x(99)90082-2. PMID 10579370.
  7. ^ Aringhieri S, Carli M, Kolachalam S, Verdesca V, Cini E, Rossi M, et al. (December 2018). "Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences". Pharmacology & Therapeutics. 192: 20–41. doi:10.1016/j.pharmthera.2018.06.012. PMID 29953902. S2CID 49602956.
  8. ^ Cite error: The named reference :0 was invoked but never defined (see the help page).
  9. ^ Cite error: The named reference king was invoked but never defined (see the help page).

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search